Clinical Images and Case Reports Journal | PubMed
  • contact@literaturepublishers.org
  • Whitley Bay, NE26 2HU, England, UK
  • Submit Manuscript
Article Details

Clinical Image

Volume 6, Issue 10 (October Issue)

Chronic Lymphocytic Leukemia Infiltrating in the Brain

Arnardottir Sitare* and Hamilton Walley

Department of Internal Medicine, Saint Louis Hospital, Paris VII University, France

*Corresponding author: Arnardottir Sitare, Department of Internal Medicine, Saint Louis Hospital, Paris VII University, France.
E-mail: arnasitar.univer@gmail.com

Received: September 08, 2024; Accepted: September 24, 2024; Published: October 15, 2024

Citation: Sitare A, Walley H. Chronic Lymphocytic Leukemia Infiltrating in the Brain. Clin Image Case Rep J. 2024; 6(10): 426.

Chronic Lymphocytic Leukemia Infiltrating in the Brain
Abstract

A 72 year-old man presented to the emergency department with two weeks of poor oral intake and progressive confusion. Two years prior, he was found to have a lymphocytosis and was diagnosed with chronic lymphocytic leukemia (CLL). Fluorescence in situ hybridization of CLL cells showed trisomy 12 in 32% of nuclei without TP53 or IGHV mutations. CT scan of the head was normal (Figure 1A) and CT angiogram of the head/neck showed patent vasculature. Transthoracic echocardiogram showed left ventricular enlargement and apical ballooning, concerning for stress-induced cardiomyopathy.

Brain MRI showed patchy T2 hyperintense signal involving the bilateral cerebral hemispheres, brainstem, and right cerebellum (Figure 1B-E). Lumbar puncture revealed 31 total nucleated cells (89% lymphocytes), protein of 75 mg/dL, and glucose of 75 mg/dL (serum glucose 148 mg/dL). Cerebrospinal fluid (CSF) flow cytometry was positive for malignant CD5+ B cells, consistent with CLL. CSF infectious studies resulted positive for human herpesvirus 6 and Ebstein-Barr virus polymerase chain reaction. Brain pathology obtained through needle biopsy confirmed perivascular CLL infiltrates of dimly CD20+ B cells with weak coexpression of PAX5, CD5, and CD23. There was no pathologic evidence of high-grade transformation or infection. Despite treatment with Bruton tyrosine kinase inhibitor, zanubrutinib, and initial radiographic response, he worsened, and care was withdrawn.

Symptomatic CNS involvement by CLL is extremely rare but portends a poor prognosis (survival in months) when abnormalities are extensive. Clearance of CSF from CLL after treatment and limited leptomeningeal involvement may be associated with better overall survival.